These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38320207)

  • 1. Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.
    Oertel WH; Müller HH; Unger MM; Schade-Brittinger C; Balthasar K; Articus K; Brinkman M; Venuto CS; Tracik F; Eberling J; Eggert KM; Kamp C; Kieburtz K; Boyd JT
    NEJM Evid; 2023 Sep; 2(9):EVIDoa2200311. PubMed ID: 38320207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Lixisenatide in Early Parkinson's Disease.
    Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
    N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Prasinezumab in Early-Stage Parkinson's Disease.
    Pagano G; Taylor KI; Anzures-Cabrera J; Marchesi M; Simuni T; Marek K; Postuma RB; Pavese N; Stocchi F; Azulay JP; Mollenhauer B; López-Manzanares L; Russell DS; Boyd JT; Nicholas AP; Luquin MR; Hauser RA; Gasser T; Poewe W; Ricci B; Boulay A; Vogt A; Boess FG; Dukart J; D'Urso G; Finch R; Zanigni S; Monnet A; Pross N; Hahn A; Svoboda H; Britschgi M; Lipsmeier F; Volkova-Volkmar E; Lindemann M; Dziadek S; Holiga Š; Rukina D; Kustermann T; Kerchner GA; Fontoura P; Umbricht D; Doody R; Nikolcheva T; Bonni A; ;
    N Engl J Med; 2022 Aug; 387(5):421-432. PubMed ID: 35921451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
    Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
    N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.
    Villafane G; Thiriez C; Audureau E; Straczek C; Kerschen P; Cormier-Dequaire F; Van Der Gucht A; Gurruchaga JM; Quéré-Carne M; Evangelista E; Paul M; Defer G; Damier P; Remy P; Itti E; Fénelon G
    Eur J Neurol; 2018 Jan; 25(1):120-127. PubMed ID: 28960663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
    Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of Cinpanemab in Early Parkinson's Disease.
    Lang AE; Siderowf AD; Macklin EA; Poewe W; Brooks DJ; Fernandez HH; Rascol O; Giladi N; Stocchi F; Tanner CM; Postuma RB; Simon DK; Tolosa E; Mollenhauer B; Cedarbaum JM; Fraser K; Xiao J; Evans KC; Graham DL; Sapir I; Inra J; Hutchison RM; Yang M; Fox T; Budd Haeberlein S; Dam T;
    N Engl J Med; 2022 Aug; 387(5):408-420. PubMed ID: 35921450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Deferiprone in Parkinson's Disease.
    Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
    N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
    BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.